TABLE 1.
Clinical characteristics of the study cohort.
| Variable | Low MCP‐1 (n = 123) | High MCP‐1 (n = 124) | p‐value |
|---|---|---|---|
| Age (years), mean (range) | 54.90 (59.7) | 55.4 (56.5) | NS |
| Oestrogen receptor status, n (%) | NS | ||
| Positive | 90 (71.79) | 90 (71.90) | |
| Negative | 33 (28.21) | 34 (28.10) | |
| Tumour size (mm), median (IQR) | 20.0 (13.5) | 17.5 (12.0) | NS |
| Grade (primary tumour), n (%) | NS | ||
| 1 | 22 (17.89) | 15 (12.10) | |
| 2 | 43 (34.96) | 50 (40.32) | |
| 3 | 58 (47.15) | 59 (50.43) | |
| Lymph node involvement, n (%) | 59 (48.36) | 54 (43.90) | NS |
| Treatment, n (%) | |||
| Endocrine therapy | 59 (47.20) | 66 (53.23) | NS |
| Chemotherapy | 48 (39.02) | 52 (41.94) | NS |
| Distant relapse, n (%) | 86 (52.5) | 95 (47.5) | NS |
Note: Age and tumour size were analysed using a linear regression. Grade, lymph node involvement, treatment and distant relapse were analysed by Chi‐squared testing.
Abbreviations: IQR, interquartile range; MCP‐1, monocyte chemoattractant protein‐1; NS, not significant.